Drug comparisons
Alogliptin vs Tolazamide
Compare Alogliptin (DPP-4 inhibitor) vs Tolazamide (sulfonylurea) for type 2 diabetes: efficacy, hypoglycemia risk, heart failure warning, and patient suitability.
No comparison dimensions are available for this page.
Clinical context
This comparison is typically triggered when evaluating a switch from an older first-generation sulfonylurea to a DPP-4 inhibitor in type 2 diabetes patients with cardiovascular or hypoglycemia concerns.
Bottom line
Alogliptin and Tolazamide both lower blood glucose in type 2 diabetes but differ markedly in mechanism, hypoglycemia risk, and cardiovascular safety, so the better choice is highly patient-specific.
All medication comparisons